What You Should Know:
- AbbVie and Gilgamesh Pharmaceuticals Inc. have announced a definitive agreement for AbbVie to acquire Gilgamesh's lead investigational candidate, bretisilocin, which is in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
- The deal is valued at up to $1.2B, which includes an upfront payment and development milestones. As part of the acquisition, Gilgamesh will spin off a new entity that will
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Ginkgo, Tangible & Inductive Bio Launch AI-Powered Lab-in-the-Loop Drug Discovery
What You Should Know:
- Ginkgo Bioworks has announced a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven "lab-in-the-loop" drug discovery more accessible to the industry.
- The collaboration combines high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into one seamless, integrated service. This is designed to help scientists discover better drugs with fewer resources by delivering
Read More
OSPRI Launches as Vertically-Integrated Biotech Company with $30M
What You Should Know:
- Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a new biotechnology company specializing in polymerase chain reaction (PCR)-based infectious disease detection.
- The merger creates one of the world's first fully vertically-integrated molecular testing platforms.
Addressing Cost and Complexity in PCR Testing
OSPRI will develop and deliver advanced tools to improve access to high-quality
Read More
Ryght AI Announces Partnership with Biorasi to Transform Feasibility Accuracy in Clinical Trials
What You Should Know:
- Ryght AI, an AI clinical trial developer, today announced a partnership with Biorasi, a global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies.
- The collaboration will bring advanced, AI-driven feasibility capabilities to biotech and biopharma sponsors.
Redefine Clinical Trial Feasibility with AI Digital Twin Technology
Ryght AI is reshaping clinical research through a next-generation platform
Read More
FemTech: Gameto Secures $44M to Advance Stem Cell Therapy for Infertility and Menopause
What You Should Know:
- Gameto, a clinical-stage biotechnology company focused on reproductive health secures $44M in Series C funding, bringing its total capital raised to a leading $127M.
- The funding, led by Overwater Ventures with participation from multiple investors including Insight Partners and RA Capital, will support the completion of the ongoing Phase 3 trial for its lead program, Fertilo.
Fertilo: A Paradigm Shift in IVF
Fertilo is a novel therapy designed to
Read More
Garden Launches BLOOM to Make AI Drug Design IP-Aware in Real Time
What You Should Know:
- Garden has announced the launch of BLOOM (Branching Lookup Optimized for Organic Molecules), a Markush structure search engine designed to give AI drug-design teams near-instant verification of small-molecule intellectual property (IP) landscapes.
- As AI models accelerate the pace of molecule generation, the critical bottleneck has shifted from discovery to due diligence—ensuring that a new candidate isn't already patented. BLOOM eliminates this bottleneck,
Read More
New Vivalink Survey Finds Nearly 90% of Americans Open to Remote Clinical Trials
What You Should Know:
- A new survey shows that remote clinical trials are not just a convenient option but a key factor in whether people choose to participate in research at all.
- The survey, conducted by digital healthcare solutions provider Vivalink, found that nearly 90% of Americans are open to participating in fully remote trials, signaling a major shift in patient expectations.
A Clear Preference for Virtual Trials
The survey, which polled over 200 U.S. adults,
Read More
M&A: Evident to Acquire Digital Pathology Solution Pramana
What You Should Know:
- Evident, a leader in clinical microscopy and superior optics, today announced a definitive agreement to acquire Pramana, Inc., a manufacturer of digital pathology solutions. Financial details of the acquisition were not disclosed.
- The strategic acquisition brings together Pramana’s cutting-edge autonomous whole slide imaging technologies with Evident’s longstanding expertise to revolutionize the market for digital pathology solutions and usher in what both
Read More
Why MedTech Needs Regulatory Intelligence, Not Just Regulatory Updates
In the past five years, medical device companies have faced continuous change, with new regulations, evolving standards, and increasing documentation requirements. The 2024 MTI Regulatory Report put it plainly: “time and bandwidth” have now overtaken cost as the biggest challenge for regulatory affairs teams.
This shift points to a deeper issue. The volume and pace of regulatory change have outgrown traditional compliance approaches. Tracking updates and reacting as they come is no longer
Read More
How Sensor Technology Is Transforming Clinical Trials
Clinical trials are the foundation of drug development, generating life-saving medicines for the betterment of society. But trials can be arduous, lengthy, and expensive for patients, sites, and sponsors, particularly in neurological disease trials, where phase III trials cost up to $370 million, last 7.9 years, and face a 95% failure rate among drug candidates 1,2,3. Moreover, traditional site-based data collection methods do not capture the complete picture of how patients are affected by
Read More
